Pharmacogenomic decision-making during elective surgery
The ImPreSS Trial: Implementation of Point-of-Care Pharmacogenomic Decision Support in Perioperative Care
NA · University of Chicago · NCT03729180
This study is testing whether using genetic information from blood samples can help doctors choose the safest and most effective medications for adults having elective surgery.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 1900 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Chicago (other) |
| Locations | 1 site (Chicago, Illinois) |
| Trial ID | NCT03729180 on ClinicalTrials.gov |
What this trial studies
This study involves adults scheduled for elective surgical procedures at the University of Chicago, where blood samples will be collected for preemptive genotyping. The genotyping will identify actionable germline variants that predict drug response or toxicity risk. Results will be provided to healthcare providers through a secure web portal, enabling personalized drug-gene clinical decision support. The initial phase will include approximately 100 patients over a six-month period to evaluate the integration of pharmacogenomic data into clinical practice.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 years or older who are scheduled for elective surgical procedures at the University of Chicago.
Not a fit: Patients who are undergoing or being considered for liver or kidney transplantation or those with known active or prior leukemia may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more personalized and effective medication management during and after surgery.
How similar studies have performed: While pharmacogenomic approaches are gaining traction, this specific integration of genotyping at the time of surgery is relatively novel and has not been extensively tested in similar contexts.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patients who have planned elective surgical procedures at the University of Chicago * Must be aged 18 years or older Exclusion Criteria: * Patients who have undergone, or are being actively considered for, liver or kidney transplantation * Patients with known active or prior leukemia. * Inability to understand and give informed consent to participate.
Where this trial is running
Chicago, Illinois
- University Of Chicago Medicine Comprehensive Cancer Center — Chicago, Illinois, United States (RECRUITING)
Study contacts
- Principal investigator: Peter O'Donnell — University of Chicago
- Study coordinator: Cancer Clinical Trials Office
- Email: cancerclinicaltrials@bsd.uchicago.edu
- Phone: 1-855-702-8222
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Surgery